Nephros Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nephros in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Nephros stock.
View analyst ratings for Nephros or view top-rated stocks.

Wall Street analysts have given Nephros a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nephros wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Nephros saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 12,500 shares, an increase of 54.3% from the January 28th total of 8,100 shares. Based on an average trading volume of 19,400 shares, the days-to-cover ratio is currently 0.6 days.
View Nephros' Short Interest.

Nephros is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Nephros.

Nephros will be holding an earnings conference call on Monday, March 1st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Nephros, Inc. (NASDAQ:NEPH) released its quarterly earnings data on Thursday, November, 5th. The company reported ($0.12) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.02. The business had revenue of $2.12 million for the quarter. Nephros had a negative net margin of 43.58% and a negative trailing twelve-month return on equity of 36.33%.
View Nephros' earnings history.

Nephros' stock was trading at $7.47 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NEPH stock has increased by 3.1% and is now trading at $7.70.
View which stocks have been most impacted by COVID-19.

Nephros updated its fourth quarter 2020 Pre-Market earnings guidance on Tuesday, January, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.3-2.3 million, compared to the consensus revenue estimate of $2.31 million.

2 brokerages have issued twelve-month price objectives for Nephros' shares. Their forecasts range from $12.50 to $16.00. On average, they anticipate Nephros' share price to reach $14.25 in the next twelve months. This suggests a possible upside of 85.1% from the stock's current price.
View analysts' price targets for Nephros or view top-rated stocks among Wall Street analysts.

Some companies that are related to Nephros include PAVmed (PAVM), Neuronetics (STIM), Soliton (SOLY), IRadimed (IRMD), RenovaCare (RCAR), TELA Bio (TELA), DarioHealth (DRIO), Isoray (ISR), Titan Medical (TMDI), Lyra Therapeutics (LYRA), PolyPid (PYPD), Repro Med Systems (KRMD), Repro-Med Systems (REPR), Nemaura Medical (NMRD) and Venus Concept (VERO).
View all of NEPH's competitors.

Nephros trades on the NASDAQ under the ticker symbol "NEPH."

Nephros' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Cowen Prime Services LLC (5.83%), Samjo Capital LLC (5.58%), HighTower Advisors LLC (0.56%) and Elkhorn Partners Limited Partnership (0.14%). Company insiders that own Nephros stock include Andrew Astor, Daron Evans and Oliver J Spandow.
View institutional ownership trends for Nephros.

NEPH stock was sold by a variety of institutional investors in the last quarter, including Elkhorn Partners Limited Partnership.
View insider buying and selling activity for Nephros or view top insider-selling stocks.

NEPH stock was purchased by a variety of institutional investors in the last quarter, including Samjo Capital LLC, Cowen Prime Services LLC, and HighTower Advisors LLC. Company insiders that have bought Nephros stock in the last two years include Andrew Astor, Daron Evans, and Oliver J Spandow.
View insider buying and selling activity for Nephros or or view top insider-buying stocks.

Shares of NEPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NEPH stock can currently be purchased for approximately $7.70.

Nephros has a market capitalization of $75.96 million and generates $10.33 million in revenue each year. The company earns $-3,420,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis.

Nephros employs 25 workers across the globe.

The official website for Nephros is www.nephros.com.

Nephros is headquartered at 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079.

Nephros' mailing address is 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079. The company can be reached via phone at 201 343 5202.